Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study.
diabetes mellitus
lanreotide
progression-free survival
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
23 Dec 2021
23 Dec 2021
Historique:
received:
11
11
2021
revised:
17
12
2021
accepted:
20
12
2021
entrez:
11
1
2022
pubmed:
12
1
2022
medline:
12
1
2022
Statut:
epublish
Résumé
The prognostic role of diabetes mellitus (DM) in advanced enteropancreatic neuroendocrine tumors (NETs) is unclear. Progression free survival (PFS) was assessed in post-hoc analyses of the 96-week, phase III, double-blind, placebo-controlled CLARINET study of lanreotide 120 mg in patients with advanced non-functional enteropancreatic NETs with DM (with/without metformin) and without DM. Of 204 patients, there were 79 with DM (lanreotide,
Identifiants
pubmed: 35008233
pii: cancers14010069
doi: 10.3390/cancers14010069
pmc: PMC8750688
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cancers (Basel). 2020 Aug 02;12(8):
pubmed: 32748870
Diabetologia. 2017 Sep;60(9):1586-1593
pubmed: 28770321
Neuroendocrinology. 2016;103(2):172-85
pubmed: 26731013
J Clin Oncol. 2017 May 1;35(13):1421-1429
pubmed: 28375706
Int J Mol Sci. 2018 Sep 20;19(10):
pubmed: 30241339
Cancer Discov. 2012 Sep;2(9):778-90
pubmed: 22926251
Gastroenterology. 2018 Aug;155(2):479-489.e7
pubmed: 29655834
Neuroendocrinology. 2015;101(2):133-42
pubmed: 25613442
Ann Oncol. 2016 Jan;27(1):68-81
pubmed: 26487581
Future Oncol. 2016 May;12(10):1251-60
pubmed: 26890290
J Clin Endocrinol Metab. 2019 Jan 1;104(1):57-73
pubmed: 30265346
Aliment Pharmacol Ther. 2010 Jan 15;31(2):169-88
pubmed: 19845567
Transl Oncol. 2020 Feb;13(2):383-392
pubmed: 31896527
Sci Rep. 2016 Oct 26;6:36073
pubmed: 27782199
Cancers (Basel). 2018 Aug 27;10(9):
pubmed: 30150555
BMC Biol. 2014 Oct 24;12:82
pubmed: 25347702
Cancer Manag Res. 2018 Oct 24;10:4881-4890
pubmed: 30425579
Future Oncol. 2017 Aug;13(19):1677-1683
pubmed: 28580793
Front Oncol. 2019 Sep 20;9:902
pubmed: 31616628
Cancer Epidemiol Biomarkers Prev. 2018 Jun;27(6):627-635
pubmed: 29618465
Oncologist. 2017 Mar;22(3):272-285
pubmed: 28220021
N Engl J Med. 2014 Jul 17;371(3):224-33
pubmed: 25014687
Front Oncol. 2017 Oct 11;7:243
pubmed: 29075616
J Clin Endocrinol Metab. 2013 Aug;98(8):3269-79
pubmed: 23709654
Eur J Endocrinol. 2006 Jul;155(1):73-8
pubmed: 16793952